Hemolytic-uremic syndrome: Difference between revisions
No edit summary |
|||
| Line 14: | Line 14: | ||
}} | }} | ||
{{HUS}} | {{HUS}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{AHS}} | ||
{{SK}} | {{SK}} | ||
| Line 21: | Line 21: | ||
==[[Hemolytic-uremic syndrome classification|Classification]]== | ==[[Hemolytic-uremic syndrome classification|Classification]]== | ||
==[[Hemolytic-uremic syndrome pathophysiology |Pathophysiology]]== | ==[[Hemolytic-uremic syndrome pathophysiology |Pathophysiology]]== | ||
* | * Shiga toxin-induced | ||
endothelial cytotoxicity in the hemolytic uremic syndrome after infection | endothelial cytotoxicity in the hemolytic uremic syndrome after infection | ||
with | with Shiga toxin–producing Escherichia coli or other microorganisms. | ||
Thrombotic microangiopathy can also occur in patients with | Thrombotic microangiopathy can also occur in patients with | ||
pneumococcal sepsis and less commonly other infections in which | pneumococcal sepsis and less commonly other infections in which | ||
Revision as of 20:22, 16 August 2018
For patient information click here
| Hemolytic-uremic syndrome | |
| ICD-10 | D59.3 |
|---|---|
| ICD-9 | 283.11 |
| OMIM | 235400 |
| DiseasesDB | 13052 |
| MedlinePlus | 000510 |
| MeSH | D006463 |
|
Hemolytic-uremic syndrome Microchapters |
|
Differentiating Hemolytic-uremic syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hemolytic-uremic syndrome On the Web |
|
American Roentgen Ray Society Images of Hemolytic-uremic syndrome |
|
Risk calculators and risk factors for Hemolytic-uremic syndrome |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anila Hussain, MD [2] Synonyms and keywords:
Overview
Classification
Pathophysiology
- Shiga toxin-induced
endothelial cytotoxicity in the hemolytic uremic syndrome after infection with Shiga toxin–producing Escherichia coli or other microorganisms. Thrombotic microangiopathy can also occur in patients with pneumococcal sepsis and less commonly other infections in which microbial neuraminidases expose the Thomsen-Friedenreich antigen on endothelial and red cells, subjecting the cells to attack by preexisting antibodies against the antigen
Causes
Differentiating Hemolytic-uremic syndrome from other Diseases
Epidemiology and Demographics
Hemolytic uremic syndrome occurs one to three cases per 100,000 children in children one to 10 years of age annually.
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention |Cost-Effectiveness of Therapy | Future or Investigational Therapies
Case Studies
Related chapters
de:Hämolytisch-urämisches Syndrom no:Hemolytisk-uremisk syndrom nn:Hemolytisk uremisk syndrom sr:Хемолитички уремијски синдром